<TABLE border=1 cellPadding=0 cellSpacing=0 width="90%" align="center">
  <TBODY>
  <TR>
    <TD vAlign=top width="44%"><B>Growth Factor Receptor Family</B></TD>
    <TD vAlign=top width="56%"><B>Description</B></TD></TR>
  <TR>
    <TD vAlign=top width="44%">Epidermal Growth Factor Receptors 
      <P>(EGFR)</P></TD>
    <TD vAlign=top width="56%">ERBB - Frequently found to be overexpressed in 
      several tumor types glioblastomas, head/neck squamous cell carcinomas, 
      breast, oesophageal, urogenital and colorectal tumors.&nbsp; 
      Experimentation has shown that the antisense approach can reverse the 
      tumorgenicity of a colon carcinoma cell line. 
      <P>ERBB-2 - Found in carcinomas of the breast, ovaries, colon, lung, 
      liver, stomach, kidneys, oesophagus, salivery gland and bladder.&nbsp; 
      Amplification of ERBB2 occurs in 20% invasive breast carcinomas.&nbsp; It 
      increases the growth rate of breast carcinomas but not their metastatic 
      potential.</P>
      <P>ERBB-3 - High expression of ERBB3 correlated with the presence of lymph 
      node metastasis. 
      <P>ERBB-4</P></TD></TR>
  <TR>
    <TD vAlign=top width="44%">Insulin Like Receptors 
      <P>(InsulinR)</P></TD>
    <TD vAlign=top width="56%">IGFI - Primary Breast Tumors express high 
      levels of IGFI receptor.&nbsp; Antisense RNS to the IGFI receptor was 
      shown to inhibit growth of human melanoma and glioma in nude mice.&nbsp; 
      In the absence of IGFI receptor a large fraction of cells may die through 
      apoptosis, preventing efficient tumor growth. 
      <P>IRR, Ros, Ltk</P></TD></TR>
  <TR>
    <TD vAlign=top width="44%">Platelet-Derived Growth Factor Receptors 
      <P>(PDGFR)</P></TD>
    <TD vAlign=top width="56%">PDGF alpha and beta - glioblastomas, chronic 
      myelomonocytic leukaemia. 
      <P>c-KIT/SCFR - (Stem Cell Factor Receptor)&nbsp; GIST</P>
      <P>CSF1 - Found in patients with myelodysplastic syndrome. 
      <P>Flk2/Flt3</P></TD></TR>
  <TR>
    <TD vAlign=top width="44%">Fibroblast Growth Factor Receptors 
      <P>(FGFR)</P></TD>
    <TD vAlign=top width="56%">FGFR-1,FGFR-2, FGFR-3, FGFR-4, Cek2</TD></TR>
  <TR>
    <TD vAlign=top width="44%">Neurotrophin Receptor Family</TD>
    <TD vAlign=top width="56%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="44%">Angiogenic Receptors</TD>
    <TD vAlign=top width="56%">The growth of solid tumors is absolutely 
      dependent on angiogenesis.&nbsp; Some tumor cells can release angiogenic 
      factors but others recruit macrophages.&nbsp; Angiostatin is produced by 
      certain tumors and inhibits angiogenesis. 
      <P>FGF - binds to a family of receptors with two or three immunoglobuline 
      like extracellular domains.&nbsp; Overexpression contributes to growth of 
      melanomas and some breast cancers..</P>
      <P>VEGF - binds to 2 related receptors with seven immunoglobulin like 
      extracellular domains.</P></TD></TR>
  <TR>
    <TD vAlign=top width="44%">Hepatocyte Growth Factor Receptor</TD>
    <TD vAlign=top width="56%">MET - Osteosarcoma, Colorectum, thyroid, 
      ovaries, stomach, pancreas and hepatocellular carninomas.</TD></TR>
  <TR>
    <TD vAlign=top width="44%">Cytokine Receptor Family</TD>
    <TD vAlign=top width="56%">&nbsp;</TD>
  </TR>
  </TBODY>
</TABLE>